10.1038/s41416-021-01334-9 - Phase 1b/2 trial of tepotinib in sora...

This document has been corrected

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

10.1038/s41416-021-01334-9

Published Online: 2021-04-06

Journal: British Journal of Cancer•Publisher: Springer Science and Business Media LLC

Authors: Angelica Fasolo•Angelo Iacobellis•Carlo Barone•Eric Assenat•Eric Raymond•Erica Villa•Jean-Frédéric Blanc•Joerg Trojan•Josef Straub•Juergen Scheele•Karin Berghoff•Martin Wermke•Philippe Merle•Rolf Bruns•Sandrine Faivre•Thomas Decaens•Véronique Grando

This document has been corrected

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

10.1038/s41416-021-01334-9

Published Online: 2021-04-06

Journal: British Journal of Cancer

NOW

2021-06-02•Correction

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

10.1038/s41416-021-01403-z

* information provided by CrossRef

2021-06-02•Correction

10.1038/s41416-021-01403-z

* information provided by CrossRef

2021-04-06•Published

2021-06-02•Correction

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

10.1038/s41416-021-01403-z

* information provided by CrossRef

This document has been corrected

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

10.1038/s41416-021-01334-9

Published Online: 2021-04-06

Journal: British Journal of Cancer•Publisher: Springer Science and Business Media LLC